These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 27470144)

  • 1. A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells.
    Sala L; Yu Z; Ward-van Oostwaard D; van Veldhoven JP; Moretti A; Laugwitz KL; Mummery CL; IJzerman AP; Bellin M
    EMBO Mol Med; 2016 Sep; 8(9):1065-81. PubMed ID: 27470144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Mediated Shortening of Action Potentials in LQTS2 Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Duncan G; Firth K; George V; Hoang MD; Staniforth A; Smith G; Denning C
    Stem Cells Dev; 2017 Dec; 26(23):1695-1705. PubMed ID: 28992755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isogenic Sets of hiPSC-CMs Harboring Distinct KCNH2 Mutations Differ Functionally and in Susceptibility to Drug-Induced Arrhythmias.
    Brandão KO; van den Brink L; Miller DC; Grandela C; van Meer BJ; Mol MPH; de Korte T; Tertoolen LGJ; Mummery CL; Sala L; Verkerk AO; Davis RP
    Stem Cell Reports; 2020 Nov; 15(5):1127-1139. PubMed ID: 33176122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Impact of BeKm-1, a High-Affinity hERG Blocker, on Cardiomyocytes Derived from Human-Induced Pluripotent Stem Cells.
    De Waard S; Montnach J; Ribeiro B; Nicolas S; Forest V; Charpentier F; Mangoni ME; Gaborit N; Ronjat M; Loussouarn G; Lemarchand P; De Waard M
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the long QT syndrome with induced pluripotent stem cells.
    Itzhaki I; Maizels L; Huber I; Zwi-Dantsis L; Caspi O; Winterstern A; Feldman O; Gepstein A; Arbel G; Hammerman H; Boulos M; Gepstein L
    Nature; 2011 Mar; 471(7337):225-9. PubMed ID: 21240260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.
    Jehle J; Ficker E; Wan X; Deschenes I; Kisselbach J; Wiedmann F; Staudacher I; Schmidt C; Schweizer PA; Becker R; Katus HA; Thomas D
    Br J Pharmacol; 2013 Mar; 168(5):1215-29. PubMed ID: 23061993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational prediction of drug response in short QT syndrome type 1 based on measurements of compound effect in stem cell-derived cardiomyocytes.
    Jæger KH; Wall S; Tveito A
    PLoS Comput Biol; 2021 Feb; 17(2):e1008089. PubMed ID: 33591962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    El-Battrawy I; Lan H; Cyganek L; Zhao Z; Li X; Buljubasic F; Lang S; Yücel G; Sattler K; Zimmermann WH; Utikal J; Wieland T; Ravens U; Borggrefe M; Zhou XB; Akin I
    J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29574456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Testing in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1.
    Zhao Z; Li X; El-Battrawy I; Lan H; Zhong R; Xu Q; Huang M; Liao Z; Lang S; Zimmermann WH; Cyganek L; Wieland T; Akin I; Zhou XB; Borggrefe M
    Clin Pharmacol Ther; 2019 Sep; 106(3):642-651. PubMed ID: 30947366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.
    Matsa E; Rajamohan D; Dick E; Young L; Mellor I; Staniforth A; Denning C
    Eur Heart J; 2011 Apr; 32(8):952-62. PubMed ID: 21367833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward Personalized Medicine: Using Cardiomyocytes Differentiated From Urine-Derived Pluripotent Stem Cells to Recapitulate Electrophysiological Characteristics of Type 2 Long QT Syndrome.
    Jouni M; Si-Tayeb K; Es-Salah-Lamoureux Z; Latypova X; Champon B; Caillaud A; Rungoat A; Charpentier F; Loussouarn G; Baró I; Zibara K; Lemarchand P; Gaborit N
    J Am Heart Assoc; 2015 Sep; 4(9):e002159. PubMed ID: 26330336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
    Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC
    Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture.
    Lahti AL; Kujala VJ; Chapman H; Koivisto AP; Pekkanen-Mattila M; Kerkelä E; Hyttinen J; Kontula K; Swan H; Conklin BR; Yamanaka S; Silvennoinen O; Aalto-Setälä K
    Dis Model Mech; 2012 Mar; 5(2):220-30. PubMed ID: 22052944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome.
    Bellin M; Casini S; Davis RP; D'Aniello C; Haas J; Ward-van Oostwaard D; Tertoolen LG; Jung CB; Elliott DA; Welling A; Laugwitz KL; Moretti A; Mummery CL
    EMBO J; 2013 Dec; 32(24):3161-75. PubMed ID: 24213244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes.
    Mehta A; Sequiera GL; Ramachandra CJ; Sudibyo Y; Chung Y; Sheng J; Wong KY; Tan TH; Wong P; Liew R; Shim W
    Cardiovasc Res; 2014 Jun; 102(3):497-506. PubMed ID: 24623279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes.
    Shinozawa T; Nakamura K; Shoji M; Morita M; Kimura M; Furukawa H; Ueda H; Shiramoto M; Matsuguma K; Kaji Y; Ikushima I; Yono M; Liou SY; Nagai H; Nakanishi A; Yamamoto K; Izumo S
    Stem Cell Reports; 2017 Feb; 8(2):226-234. PubMed ID: 28111276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
    Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
    Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.
    Navarrete EG; Liang P; Lan F; Sanchez-Freire V; Simmons C; Gong T; Sharma A; Burridge PW; Patlolla B; Lee AS; Wu H; Beygui RE; Wu SM; Robbins RC; Bers DM; Wu JC
    Circulation; 2013 Sep; 128(11 Suppl 1):S3-13. PubMed ID: 24030418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling mutation-specific arrhythmogenic phenotypes in isogenic human iPSC-derived cardiac tissues.
    Maurissen TL; Kawatou M; López-Dávila V; Minatoya K; Yamashita JK; Woltjen K
    Sci Rep; 2024 Jan; 14(1):2586. PubMed ID: 38297132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.